Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Date:5/2/2013

tions; whether or when Arena submits for marketing approval in the EU; regulatory decisions in one territory may impact regulatory decisions in other territories and Arena's business prospects; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever by any other regulatory agency; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies m
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...
... open-label study presented ... at ... AMLN ) today announced data showing that the use of ... in more patients achieving diabetes treatment goals of,improved glucose control without ...
Cached Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... look for a connection between brain activity thought to ... of the study will be published in the December ... ,Research findings show an asymmetry of activities in the ... pattern of asymmetry found is similar to that found ...
... has recalled their turkeys and ham products voluntarily due ... of their// products. It happened only a day ... be tampered with the bacteria Listeria monocytogenes that could ... ,The company added that it had recalled ...
... Dr Abdul Qadeer Khan is reported to be in excellent ... been speculative rumors regarding his health condition despite the government’s ... ,Dr A.Q. Khan is under the best possible ... wishes. The doctors hoping to put an end to the ...
... Rosenbaum, professor in the Department of Molecular, Cellular and ... 1967, will be awarded// the prestigious 2006 E. ... highest honor for scientific research in cell biology. ... contribution on the assembly, maintenance and function of fine, ...
... of Science supports the protocol to reverse type 1 diabetes ... cells// from the spleen can add to the renewal of ... Hospital (MGH) showed the benefits of a procedure to turnaround ... from other institutions published in the March 24, 2006 issue ...
... Model Twiggy says Hollywood actresses are the true influencers of ... to contactmusic.com, Twiggy says thin actresses go on extreme diets ... disorders among fans. She wants to see more curvaceous actresses ... banning size zero, but I think Hollywood stars are the ...
Cached Medicine News:Health News:A New Research Explores Connection Between Emotionality And Alcoholism 2Health News:A New Research Explores Connection Between Emotionality And Alcoholism 3Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 2Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 3Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 4Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 5Health News:New data from NIH lab confirms protocol to reverse type 1 diabetes in mice 2
... Increase profitability by ... with simple test,sequences ... administered by ancillary ... than 5 minutes. ...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Pediatric: Tumbling "E" Acuity, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Child Acuity: Allen, Tumbling E, and Landolt C Tests....
Medicine Products: